IXI™ Platform

AI-Driven Neuroimaging Biomarker Science
for Clinical Trials

IXI™ is IXICO’s proprietary, AI-enabled neuroimaging technology platform for precision medicine, using machine learning and deep learning to drive clinical trial imaging and biomarker science insights in neurological disease research.

The platform integrates standardised high-quality image data capture, image reading, advanced analysis, and regulatory-compliant reporting of clinical data, enabling the biopharma industry to develop new medicines and diagnostic measures via a single end-to-end platform.

Insights derived from imaging biomarker data

IXI™ facilitates AI-powered biomarker discovery, validation, and analysis, enabling deeper insights into disease progression, treatment response, and patient stratification.

Key Capabilities:

Advanced Imaging Modalities
Supports a wide range of MRI and PET/SPECT biomarkers, including:
- MRI: Structural T1/T2, DTI, fMRI, MRS, ASL, QSM, neuromelanin
- PET/SPECT: Amyloid, Tau, FDG, TSPO, DAT, α-synuclein

AI-Driven Biomarker Quantification
Delivers automated volumetric analysis and disease staging, which have been validated across a number of neurodegenerative therapeutic areas.

Novel AI Algorithms and Operational Pipelines
Incorporates cutting-edge, proprietary AI neuroimaging models for academic research innovation and clinical trial use—bridging the gap between early-stage research and clinical application. These validated, scalable biomarker pipelines are deployed on behalf of biopharma clients, enabling confident and efficient integration into global trials.

Combine Analytics and Insights from Other Biomarkers
Leverage imaging, digital, and fluid biomarkers together for rich, multidimensional data and deeper clinical insight.

Consultative Science
Expert-led imaging endpoint definition, protocol optimisation, and statistical modelling to maximise trial sensitivity and reduce cohort sizes.

Post-Marketing Surveillance & Decision Support
Extends biomarker insights into real-world evidence generation and clinical decision-making.

Platform Highlights

AI-Enabled Imaging Analysis

Automates complex image processing tasks, improving speed, accuracy, and reproducibility.

Global Scalability

Proven infrastructure supporting multi-site, multi-country trials with centralised oversight.

Regulatory compliance and security

IXI™ ensures the compliance required by regulatory agencies together with best practice industry standards such as ICH-GCP, 21 CFR Part 11, ISO-13485 and ISO/EC-27001.

Modular & Customizable

Adaptable to sponsor needs, therapeutic areas, and trial phases.

Seamless Integration

Compatible with sponsor systems and workflows, requiring no additional software.

Key Features

Advanced Imaging Analysis

Diverse AI neuroimaging analytics models and tools supporting a wide range of MRI and PET/SPECT biomarkers.

End-to-End Workflow	From trial design and imaging site setup to data upload, quality control, and regulatory-compliant transfer, the IXI™ Platform ensures seamless clinical trial execution.
IXI™ Platform Interface	A secure, cloud-based portal for real-time image tracking, upload, pseudonymization, and query resolution across thousands of imaging sites worldwide.
Automated Quality Control & Scan Validation	Automated tools within the IXI Platform assess scan quality, protocol compliance, and standardisation, ensuring imaging data is trial-ready and regulatory-grade.
Centralised Radiology Reads	Flexible read workflows and bespoke read forms support blinded, multi-reader, and adjudicated reads—tailored to each protocol and therapeutic area.
Global Imaging Site Network	Over 2,000 qualified imaging sites across 75+ countries, trained and supported by IXICO’s expert teams.
Regulatory Compliance	Fully aligned with GCP, ISO13485, ISO/IEC27001, and CFR Part 11 standards.
Patient-Centric Trial Management	Tailored protocols and support for neurological patient populations, ensuring ease of participation and high-quality data capture.

Platform Evolution

The IXI™ Platform continues to evolve, expanding its capabilities beyond clinical trials into diagnostics, real-world evidence, and AI-enhanced clinical decision support. With a foundation in neuroscience and a commitment to innovation, IXICO is shaping the future of neuroimaging through:

Next-Generation Biomarkers

Including fluid biomarkers and hybrid imaging modalities.

AI-Driven Disease Modelling

Supporting earlier diagnosis, patient stratification, and predictive analytics through analysis automation.

Precision Medicine Applications

Enabling targeted therapies and individualised treatment monitoring.

Built for flexibility, scale and expansion

A flexible architecture that integrates bespoke workflows to deliver imaging endpoints with AI automated analysis tools and third-party pipelines.

Ready to explore how the IXI™ Platform can support your clinical trial or biomarker strategy?

Reach out to our team to learn more about IXI™, and discover how AI-powered neuroimaging can accelerate your research.

Contact Us